Royalty Pharma — Merger or Acquisition (November 2026)

5 slides from Royalty Pharma's merger presentation, November 2026

Slide 1: Zoryve royalty acquisition
Zoryve royalty acquisition November 2026
Slide 2: Forward Looking Statements
2 Forward Looking Statements This presentation has been prepared by Royalty Pharma plc (the “Company”), is made for informational purposes only and does not constitute an offer to sell or a solicitation of an offer to buy securities. The information set forth herein does not purport to be complete o
Slide 3: Key messages
3 Key messages 1 2 3 FDA approved therapy High unmet patient need Zoryve peak sales target of $2.3-3.0bn(2) Arcutis’ Zoryve (PDE4 inhibitor) – once- Zoryve a next-generation branded non- Long runway for growth with BNST’s daily topical for psoriasis, seborrheic steroidal topical (BNST) with similar
Slide 4: Zoryve royalty acquisition overview
4 Zoryve royalty acquisition overview Transaction overview Royalty terms Zoryve actual and consensus sales(5) (in billions) Transaction terms Royalty rate $1.6 • $100m upfront for AstraZeneca’s existing • 3% on worldwide sales $1.5 royalty on Arcutis’ Zoryve $1.3 $1.2 Stakeholders Royalty payments $
Slide 5: Zoryve: attractive opportunity in rapidly growing category leader
5 Zoryve: attractive opportunity in rapidly growing category leader Arcutis sees peak sales of $2.3-$3.0bn from current indications, reflecting share growth to 15-20%(1) (2) (2) (2) ~8m ~7% ~45% Attractive (annual patients) (dermatology patients on (share of dermatology (Zoryveasdfsa rolling 4 week